Metastatic lung cancer is a leading cause of mortality and has a mortality rate of ≥90%. Isolinderalactone (ILL) is a sesquiterpene lactone compound that has been used in traditional Chinese medicine. Research has demonstrated that ILL has antiinflammatory and antiproliferative properties;
however, to the best of our knowledge, studies investigating whether ILL can inhibit lung cancer cell metastasis have not been conducted. In the present study, 110 µM ILL was applied in the culturing of the A549 lung cancer cell line to investigate the effects of ILL on the invasion
and migration of lung cancer cells, including whether the possible mechanisms of ILL are associated with the expression of matrix metalloproteinase (MMP)2 and NME/NM23 nucleoside diphosphate kinase 1 (NM23H1) genes. The results of the present study indicated that ILL inhibited the invasion
and migration of the A549 cancer cells and exhibited a doseresponse association. ILL also significantly inhibited the protein expression and activity of MMP2 (P<0.05), exhibiting a trend similar to that of its invasion and migrationassociated properties. Further research revealed that ILL
significantly increased the expression of NM23H1 protein and inhibited the expression of βcatenin protein (P<0.05). The results of the present study is, to the best of our knowledge, the first to confirm that ILL can inhibit the invasion and migration of A549 cancer cells, with the
possible mechanisms potentially involving the inhibition of MMP-2 and β-catenin protein expression resulting from the up regulation of NM23-H1 expression.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
Document Type: Research Article
Department of Nutrition, Hungkuang University, Taichung 43302, Taiwan, R.O.C.
Department of Beauty Science, National Taichung University of Science and Technology, Taichung 40343, Taiwan, R.O.C.
Publication date: April 1, 2018
More about this publication?
Oncology Letters is a monthly, peer-reviewed journal, available in print and online, that focuses on all aspects of clinical oncology, as well as in vitro and in vivo experimental model systems relevant to the mechanisms of disease.
The principal aim of Oncology Letters is to provide the prompt publication of original studies of high quality that pertain to clinical oncology, chemotherapy, oncogenes, carcinogenesis, metastasis, epidemiology and viral oncology in the form of original research, reviews and case reports.
- Editorial Board
- Information for Authors
- Submit a Paper
- Subscribe to this Title
- Information for Advertisers
- Terms & Conditions
- Ingenta Connect is not responsible for the content or availability of external websites